PROXIMOL COMPOUND — Effervescent Granules — Halfa Bar + Hexamine + Piperazine — Kahira
1- Disclaimer
This monograph is intended for professional educational and drug-information purposes. It does not replace the current Egyptian-approved package leaflet, prescribing information, clinical assessment, laboratory testing, imaging, urine culture, or advice from a physician or pharmacist. Treatment of urinary stones and urinary tract infections should be individualized according to stone composition and location, urinary pH, renal function, infection status, pregnancy status, and other clinical factors.
We do not guarantee the accuracy, currency or completeness of information regarding medications or medical products, and official sources should be verified before making any decisions. Readers are responsible for independently verifying the information before relying on it.
Product-specific information has been distinguished, where necessary, from evidence applying to individual ingredients. Modern clinical recommendations may differ from historical or locally marketed indications.
2- Summary
Proximol Compound is an Egyptian oral effervescent urological preparation containing Halfa bar extract (Cymbopogon proximus), standardized to proximadiol, together with hexamine (methenamine) and piperazine citrate. Kahira Pharmaceuticals lists the 60-g effervescent-granule presentation with Halfa bar extract 18.6 mg, equivalent to 8 mg proximadiol, hexamine 6 g, and piperazine citrate 1 g per 100 g. OK9 TODAY
Its components have different proposed actions. Proximadiol is associated with experimental smooth-muscle antispasmodic activity and with the traditional use of Cymbopogon proximus for renal colic and facilitating passage of small urinary stones. The Egyptian Drug Authority classifies these uses as traditional uses based exclusively on long-standing use rather than modern clinical proof of efficacy. Egyptian Drug Authority
Hexamine can generate antibacterial formaldehyde in sufficiently acidic urine. Piperazine citrate has historically been incorporated into preparations intended for urate/uric-acid crystalluria; however, it is not a standard oral chemolytic agent in contemporary urolithiasis guidelines. Modern dissolution of confirmed uric-acid stones is based primarily on controlled urinary alkalinization with alkaline citrate or sodium bicarbonate. Uroweb
A particularly important pharmacological consideration is that methenamine requires an acidic urinary environment for optimal formaldehyde generation, whereas dissolution of uric-acid stones requires alkaline urine. This creates a pharmacodynamic tension between these intended effects. The net clinical effect of the complete combination on urinary pH and on the simultaneous achievement of both objectives has not been established by modern product-specific studies. Deliberate manipulation of urinary pH should therefore be medically supervised. DailyMed
3- Brand Name
PROXIMOL COMPOUND
Also marketed descriptively as Proximol Compound Effervescent Granules in Egypt.
4- Category
Urological combination preparation / urinary antiseptic and urinary-stone adjunct.
It combines a herbal smooth-muscle antispasmodic component with methenamine urinary antiseptic activity and piperazine citrate. Some Egyptian commercial drug databases classify the product under urinary/antiseptic or antigout categories, but it should not be regarded as a modern guideline-standard treatment for gout.
5- Active Ingredient
The active components are:
Halfa bar extract — Cymbopogon proximus, containing/standardized to proximadiol. Proximadiol is a bicyclic sesquiterpene diol and has demonstrated antispasmodic/smooth-muscle-relaxing activity in experimental studies. The EDA monograph identifies proximadiol as a major bioactive metabolite of the plant. Egyptian Drug Authority
Hexamine (methenamine; hexamethylenetetramine) — a urinary antiseptic whose antibacterial action depends on conversion to formaldehyde in acidic urine. DailyMed
Piperazine citrate — historically included in urinary preparations intended for uric-acid/urate crystalluria. However, contemporary urolithiasis guidelines do not recommend piperazine citrate as the standard agent for dissolution of uric-acid calculi; controlled urinary alkalinization is the established modern approach. Uroweb
6- Pharmaceutical Form & Strength
Pharmaceutical form: Oral effervescent granules.
Each 100 g contains:
- Halfa bar extract: 18.6 mg, equivalent to 8 mg proximadiol
- Hexamine: 6 g
- Piperazine citrate: 1 g OK9 TODAY
Accordingly, a calculated 5-g quantity contains approximately:
- Halfa bar extract: 0.93 mg
- Equivalent proximadiol: 0.4 mg
- Hexamine: 300 mg
- Piperazine citrate: 50 mg
These 5-g quantities are arithmetic calculations derived from the stated composition of the product. In particular, the calculated 0.4-mg proximadiol content should not be interpreted as an independently established EDA-recommended proximadiol dose. The EDA herbal monograph states that a pharmaceutical herbal-extract preparation may be administered three times daily, but does not specify 0.4 mg proximadiol per dose. Egyptian Drug Authority
The currently verified manufacturer portfolio lists a 60-g bottle presentation. OK9 TODAY
7- Manufacturer & Marketing Authorization Holder
Manufacturer:
Kahira Pharmaceuticals and Chemical Industries, Cairo, Egypt.
The Egyptian Drug Authority identifies Kahira Pharmaceuticals and Chemical Industries as a licensed Egyptian pharmaceutical manufacturer.
Marketing Authorization Holder: A separately identifiable current Marketing Authorization Holder for this exact presentation is not stated in the cited manufacturer portfolio. Formal regulatory details should be verified from the current Egyptian-approved package and leaflet.
8- Mechanism of Action
Proximadiol / Halfa bar: Cymbopogon proximus has long-standing Egyptian use as an antispasmodic and diuretic herb. Proximadiol has demonstrated experimental smooth-muscle-relaxing activity. Earlier pharmacological findings provide a plausible basis for the traditional use of the plant in renal colic and passage of small urinary stones. However, the EDA specifically characterizes these indications as being based exclusively on long-standing traditional use, and this should not be interpreted as evidence of proven modern clinical efficacy for ureteric stone expulsion. Egyptian Drug Authority
Hexamine: In sufficiently acidic urine, methenamine decomposes to release formaldehyde, which exerts nonspecific antibacterial activity within the urinary tract. Adequate urinary acidity is therefore important for the antibacterial activity of this component. Data describing this mechanism are primarily derived from methenamine preparations and should be regarded as ingredient-level pharmacology rather than product-specific clinical evidence for Proximol Compound. DailyMed
Piperazine citrate: The marketed product historically attributes effects on excess uric acid and urate crystals partly to the piperazine citrate component. However, piperazine citrate is not a standard oral chemolytic treatment in contemporary urolithiasis guidelines. For confirmed uric-acid calculi, modern oral chemolysis is based on increasing urinary pH using alkaline citrate or sodium bicarbonate with appropriate pH monitoring. OK9 TODAY
9- Spectrum of Activity
No modern, product-specific antimicrobial susceptibility spectrum has been established for Proximol Compound.
For the methenamine component, antibacterial activity results from formaldehyde generation rather than from a conventional organism-specific antibiotic target. Reference methenamine labeling describes antibacterial activity under appropriately acidic urinary conditions and emphasizes the importance of maintaining acidic urine, particularly with urea-splitting organisms such as Proteus and certain Pseudomonas strains. DailyMed
These data are derived principally from methenamine preparations such as methenamine hippurate and must therefore be regarded as ingredient-level supportive information rather than a product-specific antimicrobial spectrum for Proximol Compound.
The product should not be interpreted as having a predictable susceptibility profile comparable with a conventional antibiotic, and urine culture and susceptibility testing remain important when bacterial UTI is suspected.
10- Pharmacokinetics
No reliable contemporary product-specific pharmacokinetic studies were identified for the complete combination.
Reference pharmacokinetic data are available for other methenamine preparations, particularly methenamine hippurate. Such information may help explain the pharmacology of the methenamine component but cannot be directly extrapolated quantitatively to Proximol Compound, because the salt/formulation, dose and accompanying ingredients differ.
Accordingly, pharmacokinetic parameters reported for methenamine hippurate should be regarded as ingredient-level supportive information and not as direct pharmacokinetic measurements of Proximol Compound.
Robust human pharmacokinetic parameters for the low-dose proximadiol component of this exact formulation are not established in publicly accessible modern product-specific studies.
11- Indications
Product information from Kahira lists the preparation for:
Facilitating passage of ureteric stones, presence of excess uric acid and urate crystals in urine, and urinary tract infections such as pyelitis, cystitis and urethritis. OK9 TODAY
These manufacturer-listed indications require contemporary clinical interpretation:
For ureteric stones, Cymbopogon proximus has recognized traditional use for renal colic and removal/passage of small stones from the urinary tract. The EDA explicitly classifies these uses as based on long-standing traditional use. Management of a ureteric stone should depend on stone size, location, obstruction, symptoms, infection status and imaging findings rather than relying on this preparation alone. Egyptian Drug Authority
For uric-acid stones, modern urological guidance identifies urinary alkalinization as the basis of oral chemolysis. The EAU recommends alkaline citrate or sodium bicarbonate with urinary-pH monitoring; a target pH of approximately 7.0–7.2 is described for oral chemolysis. Uroweb
For UTI, urinary-tract infections remain a manufacturer-listed indication for Proximol Compound. However, modern product-specific clinical evidence establishing this combination as adequate therapy for an acute bacterial UTI was not identified. Evidence and modern recommendations for methenamine hippurate relate primarily to selected recurrent-UTI prevention after the current infection has been adequately treated; those recommendations should not be directly transferred to Proximol Compound as though the two formulations were clinically interchangeable. NICE
Proximol Compound should therefore not be relied upon as a substitute for appropriate antimicrobial management of an acute upper, systemic or complicated bacterial UTI.
12- Administration
The usual product dose is:
2 teaspoonfuls dissolved in approximately half a glass of water, three times daily after meals, or as directed by the physician.
Use should be medically supervised, particularly when the preparation is being used for a confirmed urinary stone, recurrent urinary symptoms, impaired renal or hepatic function, or prolonged treatment.
Adequate fluid intake is generally important in stone disease unless fluid intake has been restricted because of another medical condition.
13- Method of Preparation
Place the prescribed amount of granules in approximately half a glass of water and allow the granules to dissolve/effervesce before drinking.
The granules are intended to be taken after dissolution in water, not swallowed dry.
Keep the bottle tightly closed immediately after removing a dose because moisture can damage effervescent preparations.
14- Contraindications
Do not use in patients with known hypersensitivity to any component.
Available product information lists renal or hepatic impairment among the contraindications. Patients with clinically significant renal or hepatic impairment should therefore not use the preparation without appropriate medical evaluation.
Reference labeling for methenamine hippurate additionally contraindicates methenamine in renal insufficiency, severe hepatic insufficiency and severe dehydration. Severe dehydration should therefore be considered an important ingredient-level safety concern, although these methenamine-hippurate labeling statements should not be presented as independently verified product-specific contraindications for Proximol Compound. DailyMed
Potential interaction with sulfonamide antibacterials is addressed under Drug Interactions.
15- Warnings & Precautions
Urine pH is clinically important. Methenamine requires acidic urine for effective formaldehyde generation, whereas confirmed uric-acid stones are dissolved by increasing urinary pH. This creates opposing pharmacological requirements. The overall effect of Proximol Compound on urinary pH and the extent to which both intended actions can be achieved simultaneously have not been established by modern product-specific clinical studies. Patients should therefore not independently add urinary acidifiers or alkalinizers in an attempt to enhance the product. DailyMed
Do not rely on this product alone for an acute UTI, particularly in the presence of fever, flank pain, systemic illness, pregnancy, suspected pyelonephritis or complicated UTI. Appropriate clinical assessment, urinalysis, urine culture and antimicrobial treatment may be required. Modern NICE recommendations concerning methenamine hippurate are principally for recurrent-UTI prevention after adequate treatment of any current infection. NICE
Patients with a urinary stone require urgent medical assessment if they develop fever or chills, inability to pass urine, uncontrolled pain or vomiting, reduced urine output, suspected obstruction with infection, or deterioration in renal function.
High-dose methenamine exposure has been associated with bladder irritation, painful and frequent urination, albuminuria and gross hematuria. These findings come from high-dose methenamine exposure and should not be interpreted as product-specific incidence data for Proximol Compound. DailyMed
Severe dehydration should be avoided, particularly because it is a contraindication in current methenamine labeling and may also be undesirable in patients with urinary-stone disease. DailyMed
Adequate hydration is generally desirable in stone formers unless contraindicated. Current EAU guidance recommends a fluid intake of approximately 2.5–3.0 L/day, preferably water, and advises maintaining a 24-hour urine volume above approximately 2.5 L for stone-recurrence prevention, with individual adjustment when medical conditions require fluid restriction. Uroweb
16- Drug Interactions
Sulfonamides: Methenamine preparations should not be administered concomitantly with certain sulfonamide antibacterials because sulfonamides may form insoluble precipitates with formaldehyde in the urine. This interaction is well recognized in current methenamine labeling and is pharmacologically relevant to methenamine-containing preparations. DailyMed
Urinary alkalinizers: Potassium citrate, sodium citrate and other agents that substantially alkalinize urine may reduce the antibacterial activity of methenamine by reducing formaldehyde generation. NICE specifically advises that alkalinizing UTI sachets containing agents such as potassium citrate or sodium citrate can make methenamine hippurate less effective. This evidence relates directly to methenamine hippurate, but the underlying pH-dependent chemistry of methenamine is relevant to the hexamine component of Proximol Compound. NICE
Conversely, deliberately acidifying the urine to enhance methenamine activity may be inappropriate when treating uric-acid lithiasis, because uric-acid stone dissolution requires urinary alkalinization. Uroweb
The EDA monograph for Cymbopogon proximus reports no medicinal-product interactions for the herb. However, absence of reported interactions does not establish that clinically relevant interactions are impossible. Egyptian Drug Authority
17- Side Effects
The product information reports that nausea may rarely occur.
Methenamine-containing products may cause effects such as gastrointestinal upset, dysuria or rash. However, adverse-event frequencies reported for methenamine hippurate should not be transferred directly to Proximol Compound because the formulation and methenamine exposure differ.
High-dose or prolonged excessive methenamine exposure has been associated with significant bladder irritation, painful or frequent urination, albuminuria and hematuria. These findings represent ingredient-level high-exposure safety information rather than routine adverse effects demonstrated with the labeled dose of Proximol Compound. DailyMed
The EDA herbal monograph lists no known undesirable effects specifically for Cymbopogon proximus, while the available clinical safety evidence remains limited. Egyptian Drug Authority
Medical advice should be sought if significant rash, marked dysuria, visible blood in the urine or another serious or unexpected reaction develops.
18- Use in Special Populations
Pregnancy: Use of the combination is not recommended during pregnancy unless specifically judged appropriate by a physician on the basis of an authoritative current product source and individual clinical circumstances. The Egyptian Drug Authority specifically states that Cymbopogon proximus is not recommended during pregnancy. Reference methenamine labeling also indicates that safety in early pregnancy has not been established. Egyptian Drug Authority
Breastfeeding: The EDA states that the safety of Cymbopogon proximus during lactation has not been established and, in the absence of sufficient data, its use during lactation is not recommended. Consequently, evidence concerning methenamine alone is insufficient to establish the safety of the complete Proximol Compound combination during breastfeeding. Egyptian Drug Authority
Children: A reliable current product-specific pediatric dosage has not been established in the sources evaluated. The adult dose should not be extrapolated to children without appropriate medical supervision.
Older adults: Renal and hepatic function should be considered before use. Methenamine labeling recommends particular caution in older adults because renal, hepatic and cardiac impairment and concomitant medication are more common in this population. DailyMed
Renal/hepatic impairment: The product information contraindicates use in renal or hepatic impairment. Current methenamine labeling additionally contraindicates methenamine hippurate in renal insufficiency and severe hepatic insufficiency. Product-specific labeling and individual clinical assessment should take precedence. DailyMed
19- Storage Conditions
Store below 25°C and protect from humidity/moisture.
Keep the container tightly closed, in its original packaging, away from excessive heat and direct moisture, and out of the reach of children.
Do not use granules that have been visibly altered by moisture or after the stated expiry date.
20- Additional Sections
Packaging: The currently verified manufacturer portfolio lists a 60-g waxed sealed glass bottle of effervescent granules. OK9 TODAY
Evidence regarding Halfa bar: The Egyptian Drug Authority recognizes Cymbopogon proximus as a traditional herbal medicinal plant with diuretic and antispasmodic uses and traditional use for renal-colic relief and removal of small urinary stones. Importantly, the EDA explicitly states that these specified indications are based exclusively upon long-standing use. They should therefore not be represented as established modern clinical efficacy outcomes. Egyptian Drug Authority
Uric-acid stone treatment: Uric-acid stones are distinct from calcium oxalate, calcium phosphate, cystine, struvite and other stone types. Contemporary EAU guidance states that uric-acid stones can be treated with oral chemolysis through controlled urinary alkalinization, generally using alkaline citrate or sodium bicarbonate with pH monitoring. This does not mean that every urinary stone can be dissolved by Proximol Compound. Uroweb
Laboratory and clinical monitoring: Depending on the indication, appropriate evaluation may include urinalysis, urine culture, renal-function tests, urinary pH, imaging and—when obtainable—stone analysis. Recurrent stone formers may require metabolic evaluation.
Hydration and stone prevention: Contemporary EAU guidance recommends generous fluid intake, preferably water, generally around 2.5–3.0 L/day, with a goal of maintaining adequate urine output; individual clinical circumstances may require modification. Uroweb
Overdose: No specific product-level antidote or well-characterized modern overdose profile for the complete combination has been established. Significant overdose or the development of severe vomiting, hematuria, marked urinary irritation, neurological abnormalities or other serious symptoms warrants prompt medical assessment.
21- Frequently Asked Questions (FAQ)
Does Proximol Compound dissolve every type of kidney or ureteric stone?
No. Stone composition matters. Modern oral chemolysis is principally applicable to uric-acid stones, and current guidelines achieve dissolution through controlled urinary alkalinization with alkaline citrate or sodium bicarbonate. Calcium oxalate and many other common stones are not dissolved by this approach. Piperazine citrate itself is not a standard contemporary guideline-recommended oral chemolytic agent. Uroweb
Can Proximol Compound replace antibiotics for cystitis or pyelonephritis?
No. Although urinary tract infections are included among the manufacturer's indications and the product contains methenamine, modern product-specific evidence establishing Proximol Compound as adequate stand-alone therapy for acute bacterial UTI has not been demonstrated. Evidence supporting methenamine hippurate principally concerns prevention of selected recurrent UTIs after an existing infection has been adequately treated, and it should not be directly extrapolated to this different combination product. Acute pyelonephritis, systemic or complicated UTI requires appropriate medical evaluation and treatment. OK9 TODAY
Why is urine pH important?
Hexamine requires an acidic urinary environment for effective formaldehyde generation, while dissolution of uric-acid stones requires urine to become more alkaline. These are opposing pharmacological requirements, and the net product-specific effect has not been established by modern clinical studies. Patients should not independently manipulate urinary pH while using the preparation. DailyMed
Can it be used during pregnancy?
Routine use is not recommended. The Egyptian Drug Authority specifically states that Cymbopogon proximus is not recommended during pregnancy, while methenamine safety in early pregnancy is not firmly established. Egyptian Drug Authority
Can it be used while breastfeeding?
The EDA states that safety of Cymbopogon proximus during lactation has not been established and recommends against use in the absence of sufficient data. Safety information for methenamine alone cannot establish the safety of the complete combination. Egyptian Drug Authority
Can it be taken with a sulfonamide antibiotic?
Methenamine-containing preparations should not be combined with certain sulfonamides because insoluble urinary precipitates may form through interaction with formaldehyde. DailyMed
Should patients with stones drink plenty of water?
In most stone formers, adequate fluid intake is important unless medically contraindicated. Contemporary EAU guidance advises approximately 2.5–3.0 L of fluid daily, preferably water, and recommends maintaining a 24-hour urine volume above approximately 2.5 L for recurrence prevention. Individual requirements may differ in patients with cardiac, renal or other conditions requiring fluid restriction. Uroweb
22- References
- Kahira Pharmaceuticals and Chemical Industries — Products Portfolio: Proximol Compound composition, manufacturer-listed indications and 60-g bottle presentation. OK9 TODAY
- Egyptian Drug Authority — Egyptian Herbal Monograph: Cymbopogon proximus: major constituents, traditional medicinal uses, dosage-form information, contraindications, interactions, pregnancy, lactation and adverse-effect information. Egyptian Drug Authority
- Egyptian Drug Authority — Kahira Pharmaceuticals and Chemical Industries licensing information: regulatory information concerning the Egyptian manufacturer.
- DailyMed — Methenamine Hippurate Prescribing Information: ingredient-level information concerning methenamine pharmacology, urinary acidity, contraindications, high-dose toxicity and sulfonamide interactions. These data are not product-specific clinical data for Proximol Compound. DailyMed
- NICE Guideline NG112 — Urinary tract infection (recurrent): antimicrobial prescribing: recommendations concerning methenamine hippurate as an alternative preventive treatment in selected recurrent-UTI patients and interactions with urinary alkalinizing products. NICE
- European Association of Urology — EAU Guidelines on Urolithiasis, 2026: contemporary management of urinary stones, including oral chemolysis of uric-acid stones, urine-pH monitoring, fluid intake and recurrence prevention. Uroweb
- American Urological Association — Medical Management of Kidney Stones Guideline: contemporary framework for metabolic evaluation, preventive management and follow-up of urinary-stone disease.
- LactMed — Methenamine: ingredient-specific lactation information; such data should not be interpreted as establishing the safety of the complete Proximol Compound formulation.
- Published pharmacological and phytochemical literature on Cymbopogon proximus and proximadiol: experimental evidence concerning proximadiol and smooth-muscle activity; these experimental findings should be distinguished from clinical evidence of efficacy for Proximol Compound.